Avelumab Immunotherapy Approved for Bladder Cancer (May 15, 2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading

FDA Approves Imfinzi for Treatment of Urothelial Cancer (May 11, 2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (February 16, 2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (March 14, 2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (January 21, 2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium... Continue Reading

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Latest Bladder Cancer News By Stage


Recurrent Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (March 9, 2010)

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according... Continue Reading

More Recurrent Bladder Cancer

Screening/Prevention Bladder Cancer

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

More Evidence that Diabetes Drugs Increase Risk of Bladder Cancer (August 22, 2012)

A popular class of diabetes drugs called thiazolidinediones (TZDs) increases the risk of bladder cancer, according to the results of a study published early online in the Journal of the National Cancer Institute. Bladder cancer is diagnosed in as many... Continue Reading

Diabetes Drugs May Increase Risk of Bladder Cancer (July 26, 2012)

A class of drugs called thiazolidinediones has been linked to an increased risk of bladder cancer among adults with type 2 diabetes, according to a study published early online in the Canadian Medical Association Journal. Bladder cancer is diagnosed... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Bladder Cancer

Stage III Bladder Cancer

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Study Explores New Approach to Boosting the Immune System after Cancer Treatment (August 24, 2011)

Researchers are seeking participants for a Phase II clinical trial that will explore whether an investigational treatment can help the immune system recover after cancer treatment. Cancer treatments such as chemotherapy and radiation therapy often deplete... Continue Reading

More Stage III Bladder Cancer

Stage IV/Metastatic Bladder Cancer

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Adding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence (April 30, 2012)

Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, according to the results of a study published in the New England Journal of Medicine.[1] Bladder cancer is... Continue Reading

More Stage IV/Metastatic Bladder Cancer

Stages 0-I Bladder Cancer

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Study Compares Two Types of BCG for Bladder Cancer (April 10, 2012)

For non-muscle-invasive bladder cancer, use of theConnaughtstrain of bacillus Calmette-Guérin (BCG) may be more effective at preventing recurrences than the Tice strain of BCG. These results—from a Phase III clinical trial—were presented at the 2012... Continue Reading

More Stages 0-I Bladder Cancer

Stages II-III Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Adding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence (April 30, 2012)

Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, according to the results of a study published in the New England Journal of Medicine.[1] Bladder cancer is... Continue Reading

Study Explores New Approach to Boosting the Immune System after Cancer Treatment (August 24, 2011)

Researchers are seeking participants for a Phase II clinical trial that will explore whether an investigational treatment can help the immune system recover after cancer treatment. Cancer treatments such as chemotherapy and radiation therapy often deplete... Continue Reading

Liposomal Cisplatin Safe for Patients with Renal Insufficiency (June 14, 2011)

Liposomal cisplatin (Nanoplatin®), a chemotherapy drug still in clinical trials, does not cause damage to the kidneys and appears to provide at least equal anti-cancer effects as cisplatin (Platinol®) among cancer patients with renal insufficiency.... Continue Reading

More Stages II-III Bladder Cancer